MARKET

NGNE

NGNE

Neurogene
NASDAQ
23.90
-1.20
-4.78%
After Hours: 23.90 0 0.00% 19:30 11/12 EST
OPEN
24.77
PREV CLOSE
25.10
HIGH
24.99
LOW
22.70
VOLUME
237.85K
TURNOVER
--
52 WEEK HIGH
43.66
52 WEEK LOW
15.93
MARKET CAP
494.75M
P/E (TTM)
-4.7009
1D
5D
1M
3M
1Y
5Y
1D
Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
NASDAQ · 1d ago
Neurogene price target lowered to $60 from $65 at H.C. Wainwright
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Roivant Sciences (ROIV), Neurogene (NGNE)
TipRanks · 2d ago
Canaccord Genuity Keeps Their Buy Rating on Neurogene (NGNE)
TipRanks · 2d ago
Neurogene Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
Neurogene Price Target Cut to $60.00/Share From $65.00 by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60
Benzinga · 2d ago
Neurogene Inc. Reports Third Quarter 2026 Financial Results and NGN-401 Clinical Updates
NASDAQ · 3d ago
More
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Webull offers Neurogene Inc stock information, including NASDAQ: NGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGNE stock methods without spending real money on the virtual paper trading platform.